Literature DB >> 9626129

Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome.

L Seippel1, T Bäckström.   

Abstract

Premenstrual syndrome (PMS) is characterized by distressing somatic and behavioral symptoms that develop after ovulation, reach a maximum during the premenstrual days, and disappear within 4 days after the onset of menstruation. Corpus luteum formation is necessary for the presence of symptoms, but the role of luteal hormones is unclear. The aim of this work was to investigate the relationship between sex hormone serum concentrations and premenstrual symptom severity in patients with PMS. Mental and physical symptoms were marked on a validated visual analog scale by 30 PMS patients every evening. Daily blood samples were taken in the luteal phase and in most of the follicular phase. Estradiol, progesterone, FSH, and LH were analyzed. Symptom severity was calculated as the number of negative symptoms expressed per day and as summarized scores of negative ratings. Based on premenstrual hormone concentrations and using the median split method, patients were divided into groups with high and low hormone levels. The pattern of expressed symptoms and summarized scores during the menstrual cycle was similar for the 2 groups. High concentration of luteal-phase estradiol and LH were related to the severity of negative premenstrual symptoms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626129     DOI: 10.1210/jcem.83.6.4899

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  The pathophysiologic background for current treatments of premenstrual syndromes.

Authors:  Uriel Halbreich
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

2.  Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.

Authors:  Lotta Andréen; Inger Sundström-Poromaa; Marie Bixo; Sigrid Nyberg; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2006-05-25       Impact factor: 4.530

3.  Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro.

Authors:  Qi YE; Qiao-yan ZHANG; Cheng-jian ZHENG; Yang WANG; Lu-ping QIN
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

Review 4.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

5.  Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome.

Authors:  S Quaranta; M A Buscaglia; M G Meroni; E Colombo; S Cella
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder.

Authors:  Sheryl S Smith; Yevgeniy Ruderman; Cheryl Frye; Gregg Homanics; Maoli Yuan
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 7.  The role of hormones and hormonal treatments in premenstrual syndrome.

Authors:  Torbjörn Bäckström; Lotta Andreen; Vita Birzniece; Inger Björn; Inga-Maj Johansson; Maud Nordenstam-Haghjo; Sigrid Nyberg; Inger Sundström-Poromaa; Göran Wahlström; Mingde Wang; Di Zhu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

8.  Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.

Authors:  Susan Thys-Jacobs; Don McMahon; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2007-10-23       Impact factor: 5.958

Review 9.  Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions.

Authors:  Cheryl A Frye
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

10.  Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder).

Authors:  Stephanie Collins Reed; Frances R Levin; Suzette M Evans
Journal:  Horm Behav       Date:  2008-03-07       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.